Clinical trial
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's…
NCT00117156 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00117156 |
|---|---|
| Title | Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma |
| Official title | A Phase II Study of Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center Massachusetts General Hospital University of Rochester Genentech, Inc. Industry Biogen |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, Non-Hodgkin, MALT Lymphoma |
| Intervention type | Drug |
| Interventions | Fludarabine, Rituximab |
| Enrollment | 26 |
| Start date | Dec 1, 2003 |
| Primary completion | Oct 1, 2008 |
| Completion | Jan 1, 2012 |
| First posted | Jul 4, 2005 |
| Last update posted | Aug 1, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: